Michael L. Jackson, PhD, MPH, focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Kaiser Permanente Washington Health Research Institute (KPWHRI) principal investigator for the United States Influenza Vaccine Effectiveness (US Flu VE) Network. Using information from five sites across the country, including Kaiser Permanente Washington, this network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies.
In addition, Dr. Jackson is using data collected by the US Flu VE Network to build a simulation model for the spread of influenza, with a specific focus on understanding when new strains of the influenza virus can out-compete existing strains. This work, funded by the National Institutes of Health, aims to improve our ability to correctly choose which strains of the influenza virus to include in seasonal influenza vaccines. He also uses simulation models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenzae type b (Hib) and Neisseria meningitidis.
Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the safety of childhood immunizations and develops methods for using managed care data for vaccine safety studies.
While studying for his PhD at the University of Washington, Dr. Jackson was a graduate research associate with KPWHRI from 2002 to 2007, and then a postdoctoral fellow at KPWHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to KPWHRI as an assistant investigator in 2010. He is an affiliate associate professor at the University of Washington School of Public Health.
Disease burden, risk factors, transmission dynamics, surveillance and response
Rates of adverse events, safety of new vaccines
Methodology, removing bias in effectiveness estimates
DeSilva M, Vazquez-Benitez G, Nordin JD, Lipkind HS, Klein NP, Cheetham TC, Naleway AL, Hambidge SJ, Lee GM, Jackson ML, McCarthy NL, Kharbanda EO. Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017 Jun 22;35(29):3655-3660. doi: 10.1016/j.vaccine.2017.05.041. Epub 2017 May 25. PubMed
Kharbanda EO, Vazquez-Benitez G, Romitti PA, Naleway AL, Cheetham TC, Lipkind HS, Klein NP, Lee G, Jackson ML, Hambidge SJ, McCarthy N, DeStefano F, Nordin JD, Vaccine Safety Datalink. First trimester influenza vaccination and risks for major structural birth defects in offspring. J Pediatr. 2017 May 24. pii: S0022-3476(17)30586-3. doi: 10.1016/j.jpeds.2017.04.039. [Epub ahead of print]. PubMed
Ortiz JR, Jackson ML, Hombach J. Announcing the publication of a WHO guide to the design and interpretation of observational influenza vaccine effectiveness studies. Clin Infect Dis. 2017 Jul 15;65(2):352. doi: 10.1093/cid/cix339 PubMed
Ferdinands JM, Foppa IM, Fry AM, Flannery BL, Belongia EA, Jackson ML. Re: "invited commentary: beware the test-negative design". Am J Epidemiol. 2017 Apr 1;185(7):613. doi: 10.1093/aje/kww227.
Jackson ML, Fry AM, Katz MA, Lara C, Skowronski DM, Sur D, Victor JC, Zanab SMA. Evaluation of influenza vaccine effectiveness: a guide to the design and interpretation of observational studies. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0
Daley MF, Glanz JM, Newcomer SR, Jackson ML, Groom HC, Lugg MM, McLean HQ, Klein NP, Weintraub ES, McNeil MM. Assessing misclassification of vaccination status: implications for studies of the safety of the childhood immunization schedule. Vaccine. 2017 Apr 4;35(15):1873-1878. doi: 10.1016/j.vaccine.2017.02.058. Epub 2017 Mar 9. PubMed
Ferdinands JM, Foppa IM, Fry AM, Flannery BL, Belongia EA, Jackson ML. Re: "invited commentary: beware the test-negative design". Am J Epidemiol. 2017 Mar 1:1. doi: 10.1093/aje/kww227. [Epub ahead of print]. No abstract available. PubMed
Flannery B, Chung JR, Thaker SN, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Foust A, Sessions W, Berman L, Spencer S, Fry AM. Interim estimates of 2016-17 seasonal influenza vaccine effectiveness - United States, February 2017. MMWR Morb Mortal Wkly Rep. 2017;66(6):167-171. doi: 10.15585/mmwr.mm6606a3. PubMed
Jackson ML, Walker R, Lee S, Larson E, Dublin S. Reply to: quality indicators of drug use and the risk of pneumonia in older adults without dementia. J Am Geriatr Soc. 2017 Feb 7. doi: 10.1111/jgs.14736. [Epub ahead of print]. PubMed
Kharbanda EO, Vazquez-Benitez G, Romitti PA, Naleway AL, Cheetham TC, Lipkind HS, Sivanandam S, Klein NP, Lee GM, Jackson ML, Hambidge SJ, Olsen A, McCarthy N, DeStefano F, Nordin JD. Identifying birth defects in automated data sources in the Vaccine Safety Datalink. Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):412-420. doi: 10.1002/pds.4153. Epub 2017 Jan 4. PubMed
Dr. Paula Lozano explains how a Learning Health System project finds Kaiser Permanente Washington members who could benefit most from preventive services.
New KPWHRI study helps confirm national guidelines that encourage people with high-risk conditions to get the shot.
Read more in Healthy Findings.
While flu vaccine effectiveness varies year to year, it still makes sense to get immunized annually.
Read about it in Live Healthy.
U.S. News & World Report, Jan 18, 2018